Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Maine for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Maine only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Maine (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Daniel Rausch (NPI 1649478827)

Field	Value
Entity Type	Individual
Organization	Daniel Rausch
Address	11 Rock Row Ste 120
City	Westbrook
State	ME
ZIP	04092
Taxonomy	Hematology & Oncology Physician
NPI Enumerated	July 10, 2007

Payer Source	Total Paid
Medicare	$541K
Medicaid	$0

Key Findings

This provider’s billing is effectively single‑payer: Total Medicare revenue is $541K and there is no Medicaid billing on file. The absence of any Medicaid claims means payer exposure is concentrated in Medicare beneficiaries rather than a mixed Medicaid/Medicare panel, which has implications for reimbursement sensitivity and patient access programs.

Revenue is highly concentrated in three injectable therapies: J9271 ($258K, 48.3% of Medicare revenue), J1569 ($117K, 21.9% of Medicare revenue), and J1439 ($37.5K, 7.0% of Medicare revenue); precomputed figures show these top three codes account for 77.2% of the provider’s Medicare revenue. That mix indicates that a few high‑revenue drug codes dominate the practice’s income stream rather than clinic visit volume or routine labs.

The CPT/HCPCS mix points to an infusion‑centric hematology/oncology practice: J9271 (pembrolizumab), J1569 (immune globulin), and J1439 (ferric carboxymaltose) are the top drug drivers, and chemotherapy administration codes such as 96413 and 96401 appear on the list. This combination suggests the provider delivers specialty infusions and supportive therapies on an outpatient basis rather than deriving most revenue from office E/M visits.

Although J9271 generates the single largest revenue share ($258K, 48.3%), the provider is not a national high‑volume outlier for that agent: J9271 ranks #1616 of 1841 providers (11th percentile) and is described as typical, unremarkable volume. Similarly, J1569 (rank #289 of 542, 47th percentile) and J1439 (rank #419 of 1209, 64th percentile) are characterized as typical volumes, so the provider appears to be a modest, regionally active infusor rather than a dominant national center for these drugs.

Clinical visit codes contribute only a small portion of revenue compared with drug administration: 99214 accounts for $12.1K (2.3% of Medicare revenue) and 99215 for $9.2K (1.7% of Medicare revenue), while several infusion administration codes (96413, 96365, 96375) are present but lower in dollar impact. This suggests operational emphasis on drug procurement and infusion throughput rather than high volumes of billable E/M visits.

The provider’s tenure is long: NPI enumerated 2007-07-10 (~19 years ago), indicating an established practice presence in Westbrook, ME. Long enumeration coupled with an infusion-heavy code mix is consistent with a stable specialty practice serving a Medicare population over many years.

Reliance on high‑priced injectable reimbursements represents a concentration risk: J9271 alone is $258K and nearly half of Medicare revenue (48.3%), and the top three drugs together make up 77.2% of Medicare revenue. While current ranks for those codes are described as typical, unremarkable volume, any changes in reimbursement or utilization for these specific agents could materially affect this provider’s revenue profile.

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

43 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	6,000	$40	$258K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	3,250	$40	$117K
J1439	Injection, ferric carboxymaltose, 1 mg	37,500	$1	$37.5K
J0881	Injection, darbepoetin alfa, 1 microgram (non-esrd use)	14,700	$1	$29.4K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	170	$110	$17.5K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	130	$100	$12.1K
99215	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a high level of medical decision making, and/or the…	70	$140	$9.2K
J1454	Injection, fosnetupitant 235 mg and palonosetron 0.25 mg	20	$330	$7K
J9217	Leuprolide acetate (for depot suspension), 7.5 mg	50	$130	$6.8K
96365	The provider administers the initial intravenous infusion of a medication or other substance for a period up to one hour to prevent, treat, or diagnose a condition or disease.	120	$50	$6K

Showing 1–10 of 43

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 43 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Maine Distribution

Daniel Rausch — 0 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Maine

Full comparison — all codes billed, vs. state median

43 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	8	10	16,450	$40	$699.2K
J1569	3	10	3,150	$40	$144.9K
J0881	5	10	15,200	$1	$47K
J1439	4	10	24,750	$1	$32.2K
J9217	6	10	120	$130	$27.9K
96413	14	30	170	$100	$20.6K
J1454	9	10	60	$340	$18.3K
99214	747	2,500	70	$70	$7.2K
96401	5	10	80	$50	$6.1K
96365	11	30	90	$50	$5.6K

Showing 1–10 of 43

Related Providers

Other providers that share a Tax Identification Number (TIN) with Daniel Rausch, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Central Maine Medical Center	ME	General Acute Care Hospital	$0	$76.1M
Can Ilyas	ME	Hematology & Oncology Physician	$3.2M	$0
David Benton	ME	Hematology & Oncology Physician	$2.6M	$0
Bridgton Hospital	ME	Critical Access Hospital	$0	$2.5M
Rumford Hospital	ME	Critical Access Hospital	$0	$2.4M
Matthew Dugan	ME	Hematology & Oncology Physician	$1.8M	$0
John Winters	ME	Hematology & Oncology Physician	$1.5M	$0
Maine Center For Cancer Medicine & Blood Disorders, P.A.	ME	Hematology & Oncology Physician	$0	$1.5M
Christian Thomas	ME	Hematology & Oncology Physician	$1.5M	$0
Devon Evans	ME	Hematology & Oncology Physician	$1.5M	$0

Nearby Providers

Other providers in the same ZIP code as Daniel Rausch, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Creative Works	ME	Developmentally Disabled Services Day Training Agency	$0	$144.1M
Woodfords Family Services	ME	Community/Behavioral Health Agency	$0	$101.5M
Safe Residential Care, LLC	ME	Physical Disabilities Residential Treatment Facility	$0	$94.6M
3rivers, Inc.	ME	Intellectual and/or Developmental Disabilities Community Based Residential Treatment Facility	$0	$78.6M
Woodfords Family Services	ME	Community/Behavioral Health Agency	$0	$46.3M
Alliance Case Management	ME	Case Management Agency	$0	$17.8M
Woodfords Family Services	ME	In Home Supportive Care Agency	$0	$11.3M
Woodfords Family Services	ME	Case Management Agency	$0	$9.4M
Mas Medical Staffing Corporation	ME	Home Health Agency	$0	$8.1M
Maine Community Homecare	ME	In Home Supportive Care Agency	$0	$8.1M

Daniel Rausch — Billing Profile & Reimbursement Data

Sign up for Daniel Rausch — Billing Profile & Reimbursement Data policy alerts

Daniel Rausch — Billing Profile & Reimbursement Data

Sign up for Daniel Rausch — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References